TRIAL DATA
Dual immunotherapy may outperform single-agent pembrolizumab in MSI-H metastatic colorectal cancerAn indirect comparison using reconstructed patient data from KEYNOTE-177 and CheckMate 8HW suggests nivolumab-ipilimumab may offer progression-free survival benefits over pembrolizumab in first-line MSI-H/dMMR metastatic disease, though grade 3/4 immune-related adverse events were higher. (ESMO Gastrointest Oncol)